Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A
- PMID: 11265772
Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A
Abstract
Regrowth of drug-resistant tumor cells is responsible for approximately half of an unselected osteosarcoma population still dying of the disease despite aggressive combination therapy. Two monoclonal antibodies, TP-1 (immunoglobulin 2a) and TP-3 (immunoglobulin 2b) are available, which specifically recognize an antigen on osteosarcoma cells. In this work, we have fused the variable (V) genes of TP-3 to a truncated fragment of Pseudomonas exotoxin A, referred to as PE38. Two immunotoxins were made that differed in the Fv portion: TP-3(scFv)-PE38, which contains a peptide linker, and TP-3(dsFv)-PE38, which contains a disulfide bond for stabilization of the association between the V domains. Recombinant TP-3 immunotoxins were expressed in Escherichia coli and purified from inclusion bodies. We describe the design and expression of these immunotoxins, and their properties with regard to antigen binding, stability, and cytotoxicity. Toxicity studies were done in mice. We found that the immunotoxins exhibited very similar in vitro properties, whereas in vivo TP-3(dsFv)-PE38 was much better tolerated than TP-3(scFv)-PE38.
Similar articles
-
Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A.J Immunother (1991). 2001 Mar;24(2):144-150. J Immunother (1991). 2001. PMID: 11449071
-
Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.Clin Cancer Res. 1995 Sep;1(9):1023-9. Clin Cancer Res. 1995. PMID: 9816075
-
In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.Cancer Res. 2004 Feb 15;64(4):1419-24. doi: 10.1158/0008-5472.can-03-0570. Cancer Res. 2004. PMID: 14973056
-
Recombinant immunotoxins for the treatment of Hodgkin's disease (Review).Int J Mol Med. 2000 Nov;6(5):509-14. doi: 10.3892/ijmm.6.5.509. Int J Mol Med. 2000. PMID: 11029515 Review.
-
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.BioDrugs. 2009;23(1):1-13. doi: 10.2165/00063030-200923010-00001. BioDrugs. 2009. PMID: 19344187 Free PMC article. Review.
Cited by
-
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.FEBS J. 2011 Dec;278(23):4683-700. doi: 10.1111/j.1742-4658.2011.08182.x. Epub 2011 Jun 2. FEBS J. 2011. PMID: 21585657 Free PMC article. Review.
-
Expression and identification of recombinant soluble single-chain variable fragment of monoclonal antibody MC3.World J Gastroenterol. 2002 Apr;8(2):258-62. doi: 10.3748/wjg.v8.i2.258. World J Gastroenterol. 2002. PMID: 11925603 Free PMC article.
-
Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives.Biomedicines. 2018 Feb 10;6(1):19. doi: 10.3390/biomedicines6010019. Biomedicines. 2018. PMID: 29439419 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources